The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections
- 24 March 2020
- journal article
- editorial
- Published by Elsevier BV in Clinica Chimica Acta; International Journal of Clinical Chemistry
- Vol. 505, 192-193
- https://doi.org/10.1016/j.cca.2020.03.031
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysisClinica Chimica Acta; International Journal of Clinical Chemistry, 2020
- Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysisClinica Chimica Acta; International Journal of Clinical Chemistry, 2020
- Angiotensin Converting EnzymesPublished by Elsevier BV ,2015
- The geographic distribution of the ACE II genotype: a novel findingGenetics Research, 2007
- Angiotensin-converting enzyme 2 in lung diseasesCurrent Opinion in Pharmacology, 2006
- A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9Circulation Research, 2000